進行子宮頸癌に対するChemoradiation療法(腫瘍)

概要

論文の詳細を見る
Cervical cancer is the most common gynecological cancer in Japan, but in recent years, the number of deaths from cervical cancer has been decreasing because of the establishment of early diagnostic modalities for cancer. However, the prognosis of advanced cervical cancer has not been improved substantially by surgical therapy alone, radiotherapy alone, or any combination of the two. Recently, five randomized controlled trials comparing cisplatin-based concurrent chemoradiation therapy with radiation alone or radiation with hydroxyurea treatment for advanced cervical cancer have demonstrated that concurrent chemoradiation may offer a significant survival advantage. On the basis of the results of these trials, the National Cancer Institute (NCI) released a Clinical Announcement stating that cisplatin-based concurrent chemoradiation therapy should be established as the first-choice treatment of advanced cervical cancer. In Japan, for several years, cisplatin-based concurrent chemoradiation therapy has been employed in the treatment of advanced cervical cancer, and whether or not the original dose and interval of administration of cisplatin that were established in Western countries can be used without modifications for Japanese patients remains a matter of controversy. In order to gather evidence in Japan on concurrent chemoradiation for advanced cervical cancer, large-scale, randomized controlled trials comparing concurrent chemoradiation with radiation alone should be conducted as soon as possible.
社団法人日本産科婦人科学会の論文
2003-08-01

進行子宮頸癌に対するChemoradiation療法(腫瘍)

スポンサーリンク

概要

著者

関連論文

スポンサーリンク